Androgen-Induced, β-Catenin-Activated Hepatocellular Adenomatosis with Spontaneous External Rupture
Abstract
:1. Introduction
2. Case Presentation
3. Pathologic Findings
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Barthelmes, L.; Tait, I.S. Liver cell adenoma and liver cell adenomatosis. HPB 2005, 7, 186–196. [Google Scholar] [CrossRef] [PubMed]
- Shen, X.Y.; Hu, X.G.; Kim, Y.B.; Kim, M.N.; Hong, S.Y.; Kim, B.W.; Wang, H.J. Molecular classification of hepatocellular adenoma: A single-center experience. Ann. Hepatobiliary Pancreat. Surg. 2019, 23, 109–114. [Google Scholar] [CrossRef]
- Nagtegaal, I.D.; Odze, R.D.; Klimstra, D.; Paradis, V.; Rugge, M.; Schirmacher, P.; Washington, K.M.; Carneiro, F.; Cree, I.A.; The WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020, 76, 182–188. [Google Scholar] [CrossRef]
- Chopra, S.; Dhall, D. Pathologic Diagnosis of Well-differentiated Hepatocellular Lesions: A Practical Approach to Diagnosis with Particular Focus in Core Needle Biopsies and Utilization of Ancillary Techniques. Adv. Anat. Pathol. 2023, 30, 307–319. [Google Scholar] [CrossRef]
- Rowan, D.J.; Yasir, S.; Chen, Z.E.; Mounajjed, T.; Erdogan Damgard, S.; Cummins, L.; Zhang, L.; Whitcomb, E.; Falck, V.; Simon, S.M.; et al. Morphologic and Molecular Findings in Myxoid Hepatic Adenomas. Am. J. Surg. Pathol. 2021, 45, 1098–1107. [Google Scholar] [CrossRef] [PubMed]
- Ishak, K.G. Hepatic neoplasms associated with contraceptive and anabolic steroids. Recent Results Cancer Res. 1979, 66, 73–128. [Google Scholar] [CrossRef]
- Westaby, D.; Portmann, B.; Williams, R. Androgen related primary hepatic tumors in non-Fanconi patients. Cancer 1983, 51, 1947–1952. [Google Scholar] [CrossRef]
- Nault, J.C.; Couchy, G.; Balabaud, C.; Morcrette, G.; Caruso, S.; Blanc, J.F.; Bacq, Y.; Calderaro, J.; Paradis, V.; Ramos, J.; et al. Molecular Classification of Hepatocellular Adenoma Associates with Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology 2017, 152, 880–894.e6. [Google Scholar] [CrossRef]
- Bioulac-Sage, P.; Sempoux, C.; Balabaud, C. Hepatocellular adenoma: Classification, variants and clinical relevance. Semin. Diagn. Pathol. 2017, 34, 112–125. [Google Scholar] [CrossRef]
- Yager, J.D.; Liehr, J.G. Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 1996, 36, 203–232. [Google Scholar] [CrossRef]
- Yamamoto, T.; Matsuda, T.; Junicho, A.; Kishi, H.; Saatcioglu, F.; Muraguchi, A. Cross-talk between signal transducer and activator of transcription 3 and estrogen receptor signaling. FEBS Lett. 2000, 486, 143–148. [Google Scholar] [CrossRef]
- Jeannot, E.; Poussin, K.; Chiche, L.; Bacq, Y.; Sturm, N.; Scoazec, J.Y.; Buffet, C.; Van Nhieu, J.T.; Bellanne-Chantelot, C.; de Toma, C.; et al. Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. Cancer Res. 2007, 67, 2611–2616. [Google Scholar] [CrossRef]
- Julien, C.; Le-Bail, B.; Ouazzani Touhami, K.; Frulio, N.; Blanc, J.F.; Adam, J.P.; Laurent, C.; Balabaud, C.; Bioulac-Sage, P.; Chiche, L. Hepatocellular Adenoma Risk Factors of Hemorrhage: Size Is Not the Only Concern!: Single-center Retrospective Experience of 261 Patients. Ann. Surg. 2021, 274, 843–850. [Google Scholar] [CrossRef] [PubMed]
- Kent, D.R.; Nissen, E.D.; Nissen, S.E.; Chambers, C. Maternal death resulting from rupture of liver adenoma associated with oral contraceptives. Obstet. Gynecol. 1977, 50 (Suppl. S1), 5s–6s. [Google Scholar]
- Gryspeerdt, F.; Aerts, R. Laparoscopic liver resection for hemorrhagic hepatocellular adenoma in a pregnant patient. Acta Chir. Belg. 2018, 118, 322–325. [Google Scholar] [CrossRef]
- Gupta, S.; Naini, B.V.; Munoz, R.; Graham, R.P.; Kipp, B.R.; Torbenson, M.S.; Mounajjed, T. Hepatocellular Neoplasms Arising in Association with Androgen Use. Am. J. Surg. Pathol. 2016, 40, 454–461. [Google Scholar] [CrossRef]
- Fankhauser, C.D.; Wettstein, M.S.; Reinhardt, M.; Gessendorfer, A.; Mostafid, H.; Hermanns, T. Indications and Complications of Androgen Deprivation Therapy. Semin. Oncol. Nurs. 2020, 36, 151042. [Google Scholar] [CrossRef]
- Mulvihill, J.J.; Ridolfi, R.L.; Schultz, F.R.; Borzy, M.S.; Haughton, P.B. Hepatic adenoma in Fanconi anemia treated with oxymetholone. J. Pediatr. 1975, 87, 122–124. [Google Scholar] [CrossRef]
- Johnson, F.L.; Lerner, K.G.; Siegel, M.; Feagler, J.R.; Majerus, P.W.; Hartmann, J.R.; Thomas, E.D. Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 1972, 300, 1273–1276. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Wang, C.; Li, W.; Meng, F.; Li, Y.; Fan, H.; Zhou, Y.; Bharathi, G.; Gao, S.; Yang, Y. Multiple hepatocellular adenomas associated with long-term administration of androgenic steroids for aplastic anemia: A case report and literature review. Medicine 2020, 99, e20829. [Google Scholar] [CrossRef] [PubMed]
- Kato, K.; Abe, H.; Hanawa, N.; Fukuzawa, J.; Matsuo, R.; Yonezawa, T.; Itoh, S.; Sato, Y.; Ika, M.; Shimizu, S.; et al. Hepatocellular adenoma in a woman who was undergoing testosterone treatment for gender identity disorder. Clin. J. Gastroenterol. 2018, 11, 401–410. [Google Scholar] [CrossRef] [PubMed]
- Toso, C.; Rubbia-Brandt, L.; Negro, F.; Morel, P.; Mentha, G. Hepatocellular adenoma and polycystic ovary syndrome. Liver Int. 2003, 23, 35–37. [Google Scholar] [CrossRef] [PubMed]
- Solbach, P.; Potthoff, A.; Raatschen, H.J.; Soudah, B.; Lehmann, U.; Schneider, A.; Gebel, M.J.; Manns, M.P.; Vogel, A. Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: A case report. BMC Gastroenterol. 2015, 15, 60. [Google Scholar] [CrossRef] [PubMed]
- Hardt, A.; Stippel, D.; Odenthal, M.; Holscher, A.H.; Dienes, H.P.; Drebber, U. Development of hepatocellular carcinoma associated with anabolic androgenic steroid abuse in a young bodybuilder: A case report. Case Rep. Pathol. 2012, 2012, 195607. [Google Scholar] [CrossRef]
- Socas, L.; Zumbado, M.; Perez-Luzardo, O.; Ramos, A.; Perez, C.; Hernandez, J.R.; Boada, L.D. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: A report of two cases and a review of the literature. Br. J. Sports Med. 2005, 39, e27. [Google Scholar] [CrossRef]
- Creagh, T.M.; Rubin, A.; Evans, D.J. Hepatic tumours induced by anabolic steroids in an athlete. J. Clin. Pathol. 1988, 41, 441–443. [Google Scholar] [CrossRef] [PubMed]
- Hernandez-Nieto, L.; Bruguera, M.; Bombi, J.; Camacho, L.; Rozman, C. Benign liver-cell adenoma associated with long-term administration of an androgenic-anabolic steroid (methandienone). Cancer 1977, 40, 1761–1764. [Google Scholar] [CrossRef]
- Martin, N.M.; Abu Dayyeh, B.K.; Chung, R.T. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. World J. Gastroenterol. 2008, 14, 4573–4575. [Google Scholar] [CrossRef]
- Sempoux, C.; Gouw, A.S.H.; Dunet, V.; Paradis, V.; Balabaud, C.; Bioulac-Sage, P. Predictive Patterns of Glutamine Synthetase Immunohistochemical Staining in CTNNB1-mutated Hepatocellular Adenomas. Am. J. Surg. Pathol. 2021, 45, 477–487. [Google Scholar] [CrossRef]
- Abdel-Hamid, N.M.; Al-Quzweny, R.M. Prevalence of Hepatocellular Carcinoma in Men and the Contribution of Androgen and its Receptor in Pathogenesis and Therapy. Curr. Mol. Pharmacol. 2023, 16, 559–563. [Google Scholar] [CrossRef]
- Gonzalez, I.A.; Torbenson, M.; Sharifai, N.; Byrnes, K.; Chatterjee, D.; Kakar, S.; Yeh, M.M.; Wu, T.T.; Zhang, X.; Jain, D. Clinicopathologic characterization of hepatocellular adenomas in men: A multicenter experience. Hum. Pathol. 2023, 138, 24–33. [Google Scholar] [CrossRef]
- Toh, M.R.; Wong, E.Y.T.; Wong, S.H.; Ng, A.W.T.; Loo, L.H.; Chow, P.K.; Ngeow, J. Global Epidemiology and Genetics of Hepatocellular Carcinoma. Gastroenterology 2023, 164, 766–782. [Google Scholar] [CrossRef]
- Singal, A.G.; Kanwal, F.; Llovet, J.M. Global trends in hepatocellular carcinoma epidemiology: Implications for screening, prevention and therapy. Nat. Rev. Clin. Oncol. 2023, 20, 864–884. [Google Scholar] [CrossRef]
- Ma, W.L.; Hsu, C.L.; Wu, M.H.; Wu, C.T.; Wu, C.C.; Lai, J.J.; Jou, Y.S.; Chen, C.W.; Yeh, S.; Chang, C. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology 2008, 135, 947–955.e5. [Google Scholar] [CrossRef] [PubMed]
- Wang, S.H.; Yeh, S.H.; Chen, P.J. The driving circuit of HBx and androgen receptor in HBV-related hepatocarcinogenesis. Gut 2014, 63, 1688–1689. [Google Scholar] [CrossRef]
- Li, C.L.; Li, C.Y.; Lin, Y.Y.; Ho, M.C.; Chen, D.S.; Chen, P.J.; Yeh, S.H. Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription after Hepatitis B Virus Integration or Point Mutation in Promoter Region. Hepatology 2019, 69, 498–512. [Google Scholar] [CrossRef]
- Nagasue, N.; Ito, A.; Yukaya, H.; Ogawa, Y. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology 1985, 89, 643–647. [Google Scholar] [CrossRef]
- Nagasue, N.; Yu, L.; Yukaya, H.; Kohno, H.; Nakamura, T. Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: Impact on intrahepatic recurrence after hepatic resection. Br. J. Surg. 1995, 82, 542–547. [Google Scholar] [CrossRef]
- Boix, L.; Castells, A.; Bruix, J.; Sole, M.; Bru, C.; Fuster, J.; Rivera, F.; Rodes, J. Androgen receptors in hepatocellular carcinoma and surrounding liver: Relationship with tumor size and recurrence rate after surgical resection. J. Hepatol. 1995, 22, 616–622. [Google Scholar] [CrossRef]
- Cohen, C.; Lawson, D.; DeRose, P.B. Sex and androgenic steroid receptor expression in hepatic adenomas. Hum. Pathol. 1998, 29, 1428–1432. [Google Scholar] [CrossRef]
- Svrcek, M.; Jeannot, E.; Arrive, L.; Poupon, R.; Fromont, G.; Flejou, J.F.; Zucman-Rossi, J.; Bouchard, P.; Wendum, D. Regressive liver adenomatosis following androgenic progestin therapy withdrawal: A case report with a 10-year follow-up and a molecular analysis. Eur. J. Endocrinol. 2007, 156, 617–621. [Google Scholar] [CrossRef]
- Buhler, H.; Pirovino, M.; Akobiantz, A.; Altorfer, J.; Weitzel, M.; Maranta, E.; Schmid, M. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 1982, 82, 775–782. [Google Scholar] [PubMed]
- Chiche, L.; Dao, T.; Salame, E.; Galais, M.P.; Bouvard, N.; Schmutz, G.; Rousselot, P.; Bioulac-Sage, P.; Segol, P.; Gignoux, M. Liver adenomatosis: Reappraisal, diagnosis, and surgical management: Eight new cases and review of the literature. Ann. Surg. 2000, 231, 74–81. [Google Scholar] [CrossRef] [PubMed]
- Ma, W.L.; Hsu, C.L.; Yeh, C.C.; Wu, M.H.; Huang, C.K.; Jeng, L.B.; Hung, Y.C.; Lin, T.Y.; Yeh, S.; Chang, C. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology 2012, 56, 176–185. [Google Scholar] [CrossRef] [PubMed]
- Truica, C.I.; Byers, S.; Gelmann, E.P. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 2000, 60, 4709–4713. [Google Scholar]
- Yeh, S.; Lin, H.K.; Kang, H.Y.; Thin, T.H.; Lin, M.F.; Chang, C. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 1999, 96, 5458–5463. [Google Scholar] [CrossRef]
- Cappellen, D.; Balabaud, C.; Bioulac-Sage, P. A difficult case of beta-catenin-mutated hepatocellular adenoma: A lesson for diagnosis. Histopathology 2019, 74, 355–357. [Google Scholar] [CrossRef]
- Rooks, J.B.; Ory, H.W.; Ishak, K.G.; Strauss, L.T.; Greenspan, J.R.; Hill, A.P.; Tyler, C.W., Jr. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979, 242, 644–648. [Google Scholar] [CrossRef]
- Torbenson, M.; Lee, J.H.; Choti, M.; Gage, W.; Abraham, S.C.; Montgomery, E.; Boitnott, J.; Wu, T.T. Hepatic adenomas: Analysis of sex steroid receptor status and the Wnt signaling pathway. Mod. Pathol. 2002, 15, 189–196. [Google Scholar] [CrossRef]
- Torbenson, M. Hepatic Adenomas: Classification, Controversies, and Consensus. Surg. Pathol. Clin. 2018, 11, 351–366. [Google Scholar] [CrossRef]
- Feng, H.; Cheng, A.S.; Tsang, D.P.; Li, M.S.; Go, M.Y.; Cheung, Y.S.; Zhao, G.J.; Ng, S.S.; Lin, M.C.; Yu, J.; et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. J. Clin. Investig. 2011, 121, 3159–3175. [Google Scholar] [CrossRef]
- Song, H.; Yu, Z.; Sun, X.; Feng, J.; Yu, Q.; Khan, H.; Zhu, X.; Huang, L.; Li, M.; Mok, M.T.S.; et al. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/beta-catenin signaling. EBioMedicine 2018, 35, 155–166. [Google Scholar] [CrossRef]
- Feng, H.; Yu, Z.; Tian, Y.; Lee, Y.Y.; Li, M.S.; Go, M.Y.; Cheung, Y.S.; Lai, P.B.; Chan, A.M.; To, K.F.; et al. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. J. Hepatol. 2015, 62, 1100–1111. [Google Scholar] [CrossRef] [PubMed]
- Yu, Z.; Gao, Y.Q.; Feng, H.; Lee, Y.Y.; Li, M.S.; Tian, Y.; Go, M.Y.; Yu, D.Y.; Cheung, Y.S.; Lai, P.B.; et al. Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. Gut 2014, 63, 1793–1804. [Google Scholar] [CrossRef] [PubMed]
- Beatty, B.G.; Paxton, R.J.; Sheibani, K.; Duda, R.B.; Williams, L.E.; Shively, J.E.; Beatty, J.D. Testis imaging with 111In-labeled anticarcinoembryonic antigen monoclonal antibody: Identification of carcinoembryonic antigen in normal germ cells. Cancer Res. 1986, 46 Pt 1, 6503–6508. [Google Scholar] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Huang, J.; Ali, T.; Feldman, D.M.; Theise, N.D. Androgen-Induced, β-Catenin-Activated Hepatocellular Adenomatosis with Spontaneous External Rupture. Diagnostics 2024, 14, 1473. https://doi.org/10.3390/diagnostics14141473
Huang J, Ali T, Feldman DM, Theise ND. Androgen-Induced, β-Catenin-Activated Hepatocellular Adenomatosis with Spontaneous External Rupture. Diagnostics. 2024; 14(14):1473. https://doi.org/10.3390/diagnostics14141473
Chicago/Turabian StyleHuang, Jialing, Towhid Ali, David M. Feldman, and Neil D. Theise. 2024. "Androgen-Induced, β-Catenin-Activated Hepatocellular Adenomatosis with Spontaneous External Rupture" Diagnostics 14, no. 14: 1473. https://doi.org/10.3390/diagnostics14141473
APA StyleHuang, J., Ali, T., Feldman, D. M., & Theise, N. D. (2024). Androgen-Induced, β-Catenin-Activated Hepatocellular Adenomatosis with Spontaneous External Rupture. Diagnostics, 14(14), 1473. https://doi.org/10.3390/diagnostics14141473